{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:29:06Z","timestamp":1787318946474,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T00:00:00Z","timestamp":1456704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T00:00:00Z","timestamp":1456704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/leu.2016.46","type":"journal-article","created":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T05:43:48Z","timestamp":1458884628000},"page":"1456-1464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":183,"title":["Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia"],"prefix":"10.1038","volume":"30","author":[{"given":"Y","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Othus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B L","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J P","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A B","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Mielcarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E H","family":"Estey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F R","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R B","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"key":"BFleu201646_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, Appelbaum FR, B\u00fcchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453\u2013474.","journal-title":"Blood"},{"key":"BFleu201646_CR2","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2010-10-265603","volume":"117","author":"V Gupta","year":"2011","unstructured":"Gupta V, Tallman MS, Weisdorf DJ . Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011; 117: 2307\u20132318.","journal-title":"Blood"},{"key":"BFleu201646_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","volume":"9","author":"JJ Cornelissen","year":"2012","unstructured":"Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornh\u00e4user M, Juliusson G et al. The European LeukemiaNet AML working party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012; 9: 579\u2013590.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFleu201646_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD . Acute myeloid leukemia. N Engl J Med 2015; 373: 1136\u20131152.","journal-title":"N Engl J Med"},{"key":"BFleu201646_CR5","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/leu.2013.318","volume":"28","author":"JM Goldman","year":"2014","unstructured":"Goldman JM, Gale RP . What does MRD in leukemia really mean? Leukemia 2014; 28: 1131.","journal-title":"Leukemia"},{"key":"BFleu201646_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bjh.12358","volume":"162","author":"D Campana","year":"2013","unstructured":"Campana D, Leung W . Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol 2013; 162: 147\u2013161.","journal-title":"Br J Haematol"},{"key":"BFleu201646_CR7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","volume":"10","author":"CS Hourigan","year":"2013","unstructured":"Hourigan CS, Karp JE . Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 2013; 10: 460\u2013471.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFleu201646_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/bmt.2012.139","volume":"48","author":"SA Buckley","year":"2013","unstructured":"Buckley SA, Appelbaum FR, Walter RB . Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant 2013; 48: 630\u2013641.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu201646_CR9","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642\u20134649.","journal-title":"J Clin Oncol"},{"key":"BFleu201646_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937\u2013951.","journal-title":"Blood"},{"key":"BFleu201646_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354\u2013365.","journal-title":"Blood"},{"key":"BFleu201646_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/leu.2014.173","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 2015; 29: 137\u2013144.","journal-title":"Leukemia"},{"key":"BFleu201646_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: is it time to move toward a minimal residual disease-based definition of complete remission. J Clin Oncol 2016; 34: 329\u2013336.","journal-title":"J Clin Oncol"},{"key":"BFleu201646_CR14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011; 29: 1190\u20131197.","journal-title":"J Clin Oncol"},{"key":"BFleu201646_CR15","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","volume":"122","author":"RB Walter","year":"2013","unstructured":"Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013; 122: 1813\u20131821.","journal-title":"Blood"},{"key":"BFleu201646_CR16","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1002\/cncr.26539","volume":"118","author":"M Fang","year":"2012","unstructured":"Fang M, Storer B, Wood B, Gyurkocza B, Sandmaier BM, Appelbaum FR . Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Cancer 2012; 118: 2411\u20132419.","journal-title":"Cancer"},{"key":"BFleu201646_CR17","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1200\/JCO.2007.15.9814","volume":"26","author":"L Maurillo","year":"2008","unstructured":"Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008; 26: 4944\u20134951.","journal-title":"J Clin Oncol"},{"key":"BFleu201646_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/cancers4020601","volume":"4","author":"RM Grubovikj","year":"2012","unstructured":"Grubovikj RM, Alavi A, Koppel A, Territo M, Schiller GJ . Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission. Cancers (Basel) 2012; 4: 601\u2013617.","journal-title":"Cancers (Basel)"},{"key":"BFleu201646_CR19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bmt.2014.9","volume":"49","author":"C Anthias","year":"2014","unstructured":"Anthias C, Dignan FL, Morilla R, Morilla A, Ethell ME, Potter MN et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transplant 2014; 49: 679\u2013683.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu201646_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/ejh.12336","volume":"93","author":"M Bastos-Oreiro","year":"2014","unstructured":"Bastos-Oreiro M, Perez-Corral A, Mart\u00ednez-Laperche C, Bento L, Pascual C, Kwon M et al. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Eur J Haematol 2014; 93: 239\u2013246.","journal-title":"Eur J Haematol"},{"key":"BFleu201646_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.leukres.2014.11.011","volume":"39","author":"G Rossi","year":"2015","unstructured":"Rossi G, Carella AM, Minervini MM, di Nardo F, Waure C, Greco MM et al. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression. Leuk Res 2015; 39: 138\u2013143.","journal-title":"Leuk Res"},{"key":"BFleu201646_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cytob.21134","volume":"86","author":"W Zeijlemaker","year":"2014","unstructured":"Zeijlemaker W, Gratama JW, Schuurhuis GJ . Tumor heterogeneity makes AML a \u2018moving target\u2019 for detection of residual disease. Cytometry B Clin Cytom 2014; 86: 3\u201314.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFleu201646_CR23","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.14694\/EdBook_AM.2014.34.e334","volume":"34","author":"Timothy A. Graubert","year":"2014","unstructured":"Graubert TA, Brunner AM, Fathi AT . New molecular abnormalities and clonal architecture in AML: from reciprocal translocations to whole-genome sequencing. Am Soc Clin Oncol Educ Book 2014, e334\u2013e340.","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"BFleu201646_CR24","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","volume":"124","author":"D Grimwade","year":"2014","unstructured":"Grimwade D, Freeman SD . Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u2018prime time\u2019? Blood 2014; 124: 3345\u20133355.","journal-title":"Blood"},{"key":"BFleu201646_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1053\/j.seminhematol.2015.04.001","volume":"52","author":"P Hokland","year":"2015","unstructured":"Hokland P, Ommen HB, Mul\u00e9 MP, Hourigan CS . Advancing the minimal residual disease concept in acute myeloid leukemia. Semin Hematol 2015; 52: 184\u2013192.","journal-title":"Semin Hematol"},{"key":"BFleu201646_CR26","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jama.2015.9643","volume":"314","author":"JM Klco","year":"2015","unstructured":"Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA 2015; 314: 811\u2013822.","journal-title":"JAMA"},{"key":"BFleu201646_CR27","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/sj.leu.2404754","volume":"21","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S et al. Aberrant marker expression patterns on the CD34+CD38\u2212 stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007; 21: 1700\u20131707.","journal-title":"Leukemia"},{"key":"BFleu201646_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","volume":"19","author":"N Goardon","year":"2011","unstructured":"Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011; 19: 138\u2013152.","journal-title":"Cancer Cell"},{"key":"BFleu201646_CR29","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood-2011-06-364182","volume":"119","author":"JM Gerber","year":"2012","unstructured":"Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L et al. A clinically relevant population of leukemic CD34(+)CD38(\u2212) cells in acute myeloid leukemia. Blood 2012; 119: 3571\u20133577.","journal-title":"Blood"},{"key":"BFleu201646_CR30","doi-asserted-by":"publisher","first-page":"e107587","DOI":"10.1371\/journal.pone.0107587","volume":"9","author":"M Terwijn","year":"2014","unstructured":"Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One 2014; 9: e107587.","journal-title":"PLoS One"},{"key":"BFleu201646_CR31","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/leu.2014.327","volume":"29","author":"C Bradbury","year":"2015","unstructured":"Bradbury C, Houlton AE, Akiki S, Gregg R, Rindl M, Khan J et al. Prognostic value of monitoring a candidate immunophenotypic leukaemic stem\/progenitor cell population in patients allografted for acute myeloid leukaemia. Leukemia 2015; 29: 988\u2013991.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201646.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201646","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201646.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:42:39Z","timestamp":1781916159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,29]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFleu201646"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.46","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,29]]},"assertion":[{"value":"17 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}